| Name | Title | Contact Details |
|---|---|---|
Mark Bodenrader |
Interim Chief Financial Officer | Profile |
Paul Burgess |
Chief Business Development and Strategic | Profile |
Susan Altschuller |
Chief Financial Officer | Profile |
Jack Homsher |
VP, People and Organizational Capability | Profile |
Richard Gleeson |
Head of Clinical and R&D Technology | Profile |
Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Your partner for nuclear medicine and molecular imaging solutions.
Bionical Emas is the first and only CRO that combines Clinical Development, Early Access Programs and Clinical Trial Supply. We build close partnerships with our clients, so we can provide you with a unique, integrated service shaped to fit your needs.